A vehicle to accelerate the transition from research to drug development.
Combining the translational research strength of the Walter and Eliza Hall Institute of Medical Research and the medicinal chemistry expertise of SYNthesis Research.
A strong and growing potfolio of projects in the small molecule drug development space.
For more information or to discuss investment opportunities.
Catalyst Therapeutics: Accelerating Small Molecule Drug Discovery
Catalyst Therapeutics Pty Ltd is an investment and project management company formed as a joint venture between the Walter and Eliza Hall Institute of Medical Research and SYNthesis Research. Our mission is to create value by accelerating proof-of-concept, cutting edge research and translating biological discoveries into new drug development candidates.
Utilising a panel of independent experts, Catalyst Therapeutics is open to investing in opportunities arising out of:
Walter and Eliza Hall Institute of Medical Research
Walter and Eliza Hall Institute collaborations
External parties, where there is strategic alignment with the interests of the Walter and Eliza Hall Institute and/or SYNthesis Research
Benefits of engagement with Catalyst Therapeutics include:
Opportunity to engage new investment sources
Access to the Australian R&D Tax Incentive
Potential access to academic/industry joint funding schemes and funds such as CRC-P and the MRFF
Access to an international network
The Walter and Eliza Hall Institute is Australia’s oldest medical research institute. It was founded in 1915 with financial support from a trust established by Eliza Hall, following the death of her husband Walter.
The vision was for an institute that ‘will be the birthplace of discoveries rendering signal service to mankind in the prevention and removal of disease and the mitigation of suffering’.
Three nationally and globally significant areas of health have been long-term central interests of our research: Cancer; Immune Disorders and Infectious Diseases.
SYNthesis Research is a small molecule drug discovery company focused on both early-stage deal flow and strategic longer-term clinical development programs. Headquartered in Melbourne Australia, SYNthesis Research has established a number of shared risk, drug discovery collaborations with biotech companies and research institutes.
The goal of these shared risk collaborations is to jointly discover and develop novel, small molecule clinical candidates across a range of therapeutic areas. The SYNthesis Research team has a proud history of delivering clinical candidates, and has already built a strong pipeline of maturing drug discovery programs with our partners in the areas of cancer and inflammatory disease.